A Dose-Ranging Study of Otilonium Bromide in Patients with Irritable Bowel Syndrome

This study has been completed.

Results will be soon available in the “Results section”

Sponsor: A. Menarini Industrie Farmaceutiche Riunite

Intervention: Otilonium bromide, tablets 20, 40, 80 mg t.i.d or Placebo for a treatment period of 4 weeks

Indication: Irritable Bowel Syndrome

This study is designed to demonstrate a dose-response relationship of otilonium bromide in treatment-sensitive functional and/or clinical efficacy variables of IBS

Study type & design: Double-blind, placebo-controlled, randomized dose-ranging study in 4 parallel groups of 24 (16 female and 8 male) patients each

Main criteria for inclusion:
- Patients with IBS diagnosed according to the Rome II Criteria;
- Age $\geq 18$ and $\leq 65$ years
- Patients who have at least a 6-month history of IBS, with at least moderate abdominal pain or discomfort occurring on at least 4 days in each of the 4 weeks prior to the study
- Accurate anamnesis to exclude in particular the lactase deficiency syndrome (requiring H2-breath tests, when clinically strongly suspected), bowel inflammatory disease, diets or drugs that may cause gastrointestinal symptoms and alvus disturbances

Main criteria for exclusion:
- Patients whose condition cannot be definitely diagnosed as IBS
- Previous severe abdominal surgery
- Other concomitant diseases which could have a relevant impact on study results
- Any malignancy
- Any concomitant treatment that could affect gastrointestinal motility and function (calcium channel blockers, anticholinergics, prostaglandin drugs, antiacids, prokinetics, meconics, laxatives, antidiarrheals, antidepressives, analgesics, tranquillizers), and which cannot be stopped participation in another clinical study within 2 months prior to enrolment